The article provides an overview of therapeutic interventions for obesity management, highlighting the increasing prevalence and health risks associated with obesity. It discusses the multifactorial nature of obesity, influenced by genetic, environmental, and behavioral factors. The review covers various therapeutic agents, including orlistat, liraglutide, tirzepatide, semaglutide, phentermine/topiramate, naltrexone/bupropion, setmelanotide, metreleptin, sibutramine, rimonabant, and lorcaserin. Each agent's mechanism of action, efficacy, and side effects are detailed, with a focus on their impact on weight loss, metabolic parameters, and overall health. The article also explores surgical interventions, particularly bariatric surgery, and its advantages and complications. Finally, it discusses future directions, emphasizing the need for personalized treatment approaches and continued research into new therapies. The conclusion underscores the evolving landscape of obesity treatment, with a particular emphasis on the potential of GLP-1 agonists and the integration of surgical and pharmacological interventions.The article provides an overview of therapeutic interventions for obesity management, highlighting the increasing prevalence and health risks associated with obesity. It discusses the multifactorial nature of obesity, influenced by genetic, environmental, and behavioral factors. The review covers various therapeutic agents, including orlistat, liraglutide, tirzepatide, semaglutide, phentermine/topiramate, naltrexone/bupropion, setmelanotide, metreleptin, sibutramine, rimonabant, and lorcaserin. Each agent's mechanism of action, efficacy, and side effects are detailed, with a focus on their impact on weight loss, metabolic parameters, and overall health. The article also explores surgical interventions, particularly bariatric surgery, and its advantages and complications. Finally, it discusses future directions, emphasizing the need for personalized treatment approaches and continued research into new therapies. The conclusion underscores the evolving landscape of obesity treatment, with a particular emphasis on the potential of GLP-1 agonists and the integration of surgical and pharmacological interventions.